Benzinga's Top Downgrades - Fifth Third Bancorp (NASDAQ:FITB)

Analysts at Morgan Stanley downgraded

Gilead Sciences, Inc. GILD

from Overweight to Equal-weight. The price target for Gilead Sciences is set to $127. Gilead Sciences shares closed at $98.27 on Thursday. UBS downgraded

T. Rowe Price Group IncTROW

from Buy to Neutral. The price target for T. Rowe Price Group has been lowered from $86 to $68. T. Rowe Price Group shares closed at $68.59 on Thursday. Analysts at Morgan Stanley downgraded

Diplomat Pharmacy Inc DPLO

from Overweight to Equal-weight. The price target for Diplomat Pharmacy has been lowered from $58 to $31. Diplomat Pharmacy shares closed at $29.50 on Thursday. UBS downgraded

LPL Financial Holdings IncLPLA

from Neutral to Sell. LPL Financial shares closed at $39.39 on Thursday. BB&T Capital downgraded

Orion Marine Group, Inc. ORN

from Buy to Hold. Orion Marine Group shares closed at $5.96 on Thursday. Analysts at Morgan Stanley downgraded

Valeant Pharmaceuticals Intl IncVRX

from Overweight to Equal-weight. The price target for Valeant Pharmaceuticals has been lowered from $284 to $200. Valeant Pharmaceuticals shares closed at $179.60 on Thursday. Analysts at Goldman Sachs downgraded

Fifth Third BancorpFITB

from Buy to Neutral. The price target for Fifth Third Bancorp has been lowered from $22.50 to $21. Fifth Third Bancorp shares closed at $18.97 on Thursday. Analysts at Stifel Nicolaus downgraded

QTS Realty Trust IncQTS

from Buy to Hold. QTS Realty shares closed at $44.34 on Thursday.

Market News and Data brought to you by Benzinga APIs